Results 11 to 20 of about 16,704,778 (257)

Timing and co-occurrence of symptoms prior to a diagnosis of light chain (AL) amyloidosis [PDF]

Blood Cancer Journal
It is well-established that most patients with systemic light chain (AL) amyloidosis have multi-organ involvement and are often diagnosed after a lag period of increasing symptoms. We leverage electronic health record (EHR) data from the TriNetX research
Ashima Singh, Aniko Szabo, Qinghua Lian, Liliana Pezzin, Rodney Sparapani, Anita D’Souza   +5 more
doaj   +2 more sources

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

Hemato, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +3 more
doaj   +1 more source

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Blood Cancer Journal, 2023
Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments in recent years, yet real-world data on the management of the disease are scarce.
G. Palladini, S. Schönland, G. Merlini, P. Milani, A. Jaccard, F. Bridoux, M. Dimopoulos, S. Ravichandran, U. Hegenbart, W. Roeloffzen, M. Cibeira, H. Agis, M. Minnema, R. Bergantim, R. Hájek, C. João, A. Leonidakis, G. Cheliotis, P. Sonneveld, E. Kastritis, A. Wechalekar   +20 more
semanticscholar   +1 more source

Systemic AL amyloidosis: current approach and future direction

OncoTarget, 2023
Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. It is a fatal disease and if not diagnosed and treated early
M. Bou Zerdan, Lewis Nasr, F. Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, F. Anwer, S. Raza, C. Chaulagain   +11 more
semanticscholar   +1 more source

Diagnosis for Chinese patients with light chain amyloidosis: a scoping review

Annals of Medicine, 2023
Background Amyloid light chain (AL) amyloidosis is the most common systemic amyloidosis. The objective of this scoping review was to map the available literature on the diagnosis of AL amyloidosis in China.Materials and Methods The published academic ...
Meilan Chen, Junru Liu, Xiaohong Wang, Xian Cao, Xin Gao, Lingjie Xu, Wang Liu, Jingnan Pi, Bin Wang, Juan Li   +9 more
doaj   +1 more source

Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series.

Blood, 2023
Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related events.
Nathalie Forgeard, D. Elessa, A. Carpinteiro, Karim Belhadj, Monique C. Minnema, M. Roussel, A. Huart, V. Javaugue, Laurent Pascal, B. Royer, Alexis Talbot, R. Gounot, U. Hegenbart, S. Schonland, L. Karlin, S. Harel, E. Kastritis, F. Bridoux, A. Jaccard, B. Arnulf   +19 more
semanticscholar   +1 more source

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis

Blood Advances, 2023
Key Points • We identified baseline factors predictive of treatment outcomes and prognostic for survival in stage IIIb AL amyloidosis.• Early hematologic and cardiac responses during treatment predict longer survival in stage IIIb AL amyloidosis.
J. Gustine, Andrew Staron, L. Mendelson, T. Joshi, D. Gopal, F. Ruberg, O. Siddiqi, V. Sanchorawala   +7 more
semanticscholar   +1 more source

Systemic amyloidosis journey from diagnosis to outcomes: a twelve-year real-world experience of a single center in a middle-income country

Orphanet Journal of Rare Diseases, 2022
Background Systemic amyloidosis is caused by the deposition of misfolded protein aggregates in tissues, leading to progressive organ dysfunction and death.
Roberta Shcolnik Szor, Fabio Fernandes, Angelina Maria Martins Lino, Leonardo Oliveira Mendonça, Fernanda Salles Seguro, Valkercyo Araujo Feitosa, Jussara Bianchi Castelli, Lecticia Barbosa Jorge, Lucas Bassolli de Oliveira Alves, Precil Diego Miranda de Menezes Neves, Evandro de Oliveira Souza, Livia Barreira Cavalcante, Denise Malheiros, Jorge Kalil, Gracia Aparecida Martinez, Vanderson Rocha   +15 more
doaj   +1 more source

Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group

Amyloid: Journal of Protein Folding Disorders, 2022
Background This guideline has been developed jointly by the European Society of Haematology and International Society of Amyloidosis recommending non-transplant chemotherapy treatment for patients with AL amyloidosis.
A. Wechalekar, M. Cibeira, S. Gibbs, A. Jaccard, Shaji K. Kumar, G. Merlini, G. Palladini, V. Sanchorawala, S. Schönland, C. Venner, M. Boccadoro, E. Kastritis   +11 more
semanticscholar   +1 more source

Daratumumab in AL amyloidosis

Blood, 2022
Abstract Light-chain amyloidosis has come far, with the first treatment getting regulatory approval in 2021. Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct fibril typing, challenges of the very advanced patient, and lack of therapies to remove ...
Ashutosh D. Wechalekar, Vaishali Sanchorawala   +1 more
openaire   +3 more sources